Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Future Oncology (London, England)|January 24, 2022
Analytical similarity as base for rituximab biosimilars in lymphoid malignancies in the clinic: a PF-05280586 case studyJeff P Sharman, Carol F Kirchhoff, Robert M RifkinJournal of Pharmaceutical Sciences|April 12, 2002
Mannitol-sucrose mixtures--versatile formulations for protein lyophilizationRobert E Johnson, Carol F Kirchhoff, Henry T GaudSeminars in Arthritis and Rheumatism|March 8, 2016
Development of biosimilarsAhmad Al-Sabbagh, Ewa Olech, Joseph E McClellan, et al.Biotechnology and Bioengineering|August 27, 2017
Biosimilars: Key regulatory considerations and similarity assessment toolsCarol F Kirchhoff, Xiao-Zhuo Michelle Wang, Hugh D Conlon, et al.Therapeutic Advances in Gastroenterology|June 22, 2019
The 'totality-of-the-evidence' approach in the development of PF-06438179/GP1111, an infliximab biosimilar, and in support of its use in all indications of the reference productJoseph E McClellan, Hugh D Conlon, Michael W Bolt, et al.Drug Discovery Today|April 28, 2015
Key considerations in the preclinical development of biosimilarsLynne A Bui, Susan Hurst, Gregory L Finch, et al.Journal of Pharmaceutical Sciences|September 7, 2004
Retrospective statistical analysis of lyophilized protein formulations of progenipoietin using PLS: determination of the critical parameters for long-term storage stabilityDerrick S Katayama, Carol F Kirchhoff, Carrie M Elliott, et al.Advances in Therapy|September 3, 2016
Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade® (Infliximab)Mazin Derzi, Theodore R Johnson, Ahmed M Shoieb, et al.Pageof 1